Bridgebio Pharma Inc. (bbio 2.5 03/15/27)
13F holders, Q1 2024 (March 31)4holders
$1.07avg. 13F price*
At the end of Q1 2024, 4 institutions reported holding Bridgebio Pharma Inc. (bbio 2.5 03/15/27) in their 13F filings. The largest holders were Lord, Abbett & Co. LLC ($5.9M), Bank of New York Mellon Corp ($538K) and Fox Hill Wealth Management ($79K).
- Company
- Bridgebio Pharma Inc. (bbio 2.5 03/15/27)
- CUSIP
- 10806XAB8
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $2.7M |
Ownership 4 holders
| Lord, Abbett & Co. LLC | 0.02% | Reduce -59.0% | 5,499,000 | $5.9M |
| Bank of New York Mellon Corp | 0.00% | No change | 500,000 | $538K |
| Fox Hill Wealth Management | 0.05% | Add +4.2% | 74,000 | $79K |
| Stonegate Investment Group, LLC | 0.00% | No change | 12,000 | $13K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.5 03/15/27) the manager owns.